FIELD: medicine, polymers.
SUBSTANCE: invention relates to conjugates consisting of a water-soluble polymer of molecular mass from 200 to 20000 Da and representing polyethylene glycol or alkyl chain to which two molecules of synthetic peptides, not less, are bound by reactive functional group and wherein each peptide comprises amino acid sequence originating from region HR1 or HR2 of human immunodeficiency virus (HIV) gp41. Invention relates to methods for using these conjugates for delivery inhibition of to HIV target-cell by addition of indicated conjugates in the amount providing effective inhibition of cell infection with indicated virus. Also, invention relates to methods for preparing conjugates by functional adding of each molecule of synthetic peptide to polymer through reactive functional group.
EFFECT: valuable biological properties of conjugates.
27 cl, 2 dwg, 6 tbl, 6 ex
| Title | Year | Author | Number |
|---|---|---|---|
| PHARMACEUTICAL COMPOUNDS FOR OPTIMISED INJECTION OF gp41 HIV DERIVED PEPTIDES AND THEIR THERAPEUTIC APPLICATION | 2003 |
|
RU2357749C2 |
| ALPHABODIES FOR HIV PENETRATION INHIBITION | 2010 |
|
RU2562165C2 |
| FUSION POLYPEPTIDES WITH ENHANCED PHARMACOKINETIC PROPERTIES | 2000 |
|
RU2279883C2 |
| APPLICATION OF COMPOSITION CONSISTING OF CATIONIC LTP PEPTIDE AND MOLECULES OF RNA AGAINST RESPIRATORY VIRUSES | 2015 |
|
RU2609857C1 |
| ROTAVIRAL PARTICLES WITH CHIMERIC SURFACE PROTEINS | 2014 |
|
RU2698049C2 |
| DERIVATIVES OF PROTEIN FUSED WITH Fc WITH HIGH DOUBLE ACTIVITY: ANTIVIRAL ACTIVITY RELATIVELY TO HIV AND IMMUNOMODULATING ACTIVITY | 2018 |
|
RU2774782C2 |
| gp41-NEUTRALIZING ANTIBODIES AND THEIR APPLICATION | 2012 |
|
RU2624046C2 |
| VIRUS-LIKE PARTICLES WITH HIGH-DENSITY COATING FOR INDUCTION OF ANTIBODY EXPRESSION | 2017 |
|
RU2813282C2 |
| COMPOSITION FOR PREVENTING AND/OR TREATING INFECTION, CAUSED BY HIV-1 | 2012 |
|
RU2603262C2 |
| ANTIBODY OR FRAGMENT THEREOF, HAVING NEUTRALISING EFFECT ON HIV, BUT NOT ON IL2 | 2005 |
|
RU2393873C2 |
